藤黄酸抑制套细胞淋巴瘤细胞株增殖和促凋亡的机理研究
|
摘要
[目的]
本研究探讨藤黄酸在体外抑制套细胞淋巴瘤细胞株Jeko-1增殖的效应及可能机理。
[方法]
以不同浓度(0、0.065、0.125、0.25、0.5、1.0、2.0、4.0μg/ml)藤黄酸处理套细胞淋巴瘤Jeko-1细胞株12h-36h,免疫组化法检测细胞Ki-67阳性表达率,细胞毒性检测(?)(CCK-8)法检测藤黄酸对Jeko-1细胞及正常人骨髓单个核细胞的增殖抑制作用：碘化丙啶(PI)染色分析检测细胞周期改变；采用Annexin V/PI双染法观察细胞形态并检测细胞的凋亡,JC-1染色法检测细胞线粒体跨膜电位(△Ψm)水平；分光光度法检测细胞半胱氨酸蛋白酶Caspase-3、Caspase-8、Caspase-9阳性细胞水平；蛋白免疫印迹术检钡(?)Bcl-2、Bax蛋白水平。
[结果]
1.藤黄酸呈时间和浓度依赖性抑制Jeko-1细胞的增殖,藤黄酸对Jeko-1细胞增殖抑制率在低浓度组(0.065、0.125、0.25μg/ml)与对照组比较差异不显著(P>0.05),较高浓度组(0.5、1.0、2.0、4.0μg/ml)与对照组比较差异显著(P<0.05)：藤黄酸对正常人骨髓单个核细胞加药组与对照组比较,差异均无显著性(P>0.05)。藤黄酸可下调Jeko-1细胞Ki67的表达,且呈药物浓度依赖性。
2.藤黄酸作用于Jeko-1细胞株24h后呈典型凋亡形态学改变,各浓度(0、0.5、1.0、2.0、4.0μg/ml藤黄酸对Jeko-1细胞作用24h的细胞周期未见明显影响。
3.藤黄酸呈浓度依赖性增高Jeko-1细胞株的损伤线粒体跨膜电位(△ψm)水平。
4.藤黄酸作用JeKo-1细胞24小时,用药标本较对照标本的caspase-3、caspase-8和caspase-9活化比例明显升高(p<0.05)。caspase-3、caspase-8、和caspase-9的活化呈现浓度依赖性。
5.藤黄酸作用Jeko-1细胞24h后,随着藤黄酸浓度的增高,Bcl-2蛋白表达逐渐下降,而Bax蛋白表达逐渐增强。与对照组相比,在1μg/ml浓度时Bax/Bcl-2蛋白比值明显增高(P<0.05)。
[结论]
1.藤黄酸呈浓度依赖性抑制JeKo-1细胞的增殖。
2.藤黄酸呈浓度依耐性诱导JeKo-1细胞凋亡,机理是通过线粒体通路和膜受体通路诱导Jeko-1细胞凋亡,其诱导凋亡作用并非通过特异的细胞周期阻滞来实现。
3.藤黄酸诱导人套细胞淋巴瘤Jeko-1细胞凋亡时,主要通过活化Caspase-3、Caspase-8, Caspase-9和受损△ψm增加途径而实现诱导细胞凋亡,藤黄酸通过减低JeKo-1细胞中Bcl-2蛋白的水平,上调Bax蛋白的水平诱导细胞凋亡。
[Objective] To study the mechanisms in gambogic acid (GA)-induced JeKo-1human Mantle Cell Lymphoma cell apoptosis in vitro.
[Methods] the proliferation of GA-treated Jeko-1cells was measured by CCK-8assay and ki-67immunocytochemical detection. Appotosis, cell cycle and mitochondrial membrane potential were measured by flow cytometric analysis. Caspase-3,-8and-9were detected by colorimetric assay. Bcl-2and Bax were analyzed by Western blot.
[Results]
1. GA inhibited Jeko-1cells' growth in a time-and dose-dependent manner. Lower GA concentration (0.065、0.125、0.25μg/ml) could not inhibit the proliferation of Jeko-1cells(P>0.05). Higher GA(0.5、1.0、2.0、4.0μg/ml) concentrationcould inhibit the proliferation of Jeko-1cells (P<0.05).
2. GA did not significantly influence the cell cycle of Jeko-1cell lines at the concentration of0、0.5、1.0、2.0、4.0μg/ml for24h.
3. The typical apoptosis morphology change could be visualized after Jeko-1cell lines were incubated with GA. GA induces apoptosis in Jeko-1cells, which was involved in reducing the membrane potential of mitochondria,
4. GA increased the apoptosis rate of Jeko-1cell line and increased activated caspase-3, caspase-8, caspase-9positive cell number for different degree in24h.
5. There was a significant decrease in Bcl-2expression and increase in Bax expression in a dose-dependent manner after the GA treatment on Jeko-1cell for24h. Compared with the control group, with the concentration of1ug/ml, ratio between Bax and Bcl-2protein increased significantly (P<0.05).
[Conclusion]
1. GA has inhibitive effect on Jeko-1cell lines' growth in a concentration dependent manner in vitro.
2. GA induces apoptosis on Jeko-1cell lines in a concentration dependent manner. The Mechanism is through the mitochondrial pathway and membrane receptor pathway induce Jeko-1cell apoptosis.The cell cycles are not disturbed obviously in Jeko-1cell lines.
3. GA induced apoptosis in human MCL Jeko-1cells by regulating Bcl-2/Bax and activating caspase-3,-8and-9via mitochondrial pathway without affecting cell cycle.
本研究探讨藤黄酸在体外抑制套细胞淋巴瘤细胞株Jeko-1增殖的效应及可能机理。
[方法]
以不同浓度(0、0.065、0.125、0.25、0.5、1.0、2.0、4.0μg/ml)藤黄酸处理套细胞淋巴瘤Jeko-1细胞株12h-36h,免疫组化法检测细胞Ki-67阳性表达率,细胞毒性检测(?)(CCK-8)法检测藤黄酸对Jeko-1细胞及正常人骨髓单个核细胞的增殖抑制作用：碘化丙啶(PI)染色分析检测细胞周期改变；采用Annexin V/PI双染法观察细胞形态并检测细胞的凋亡,JC-1染色法检测细胞线粒体跨膜电位(△Ψm)水平；分光光度法检测细胞半胱氨酸蛋白酶Caspase-3、Caspase-8、Caspase-9阳性细胞水平；蛋白免疫印迹术检钡(?)Bcl-2、Bax蛋白水平。
[结果]
1.藤黄酸呈时间和浓度依赖性抑制Jeko-1细胞的增殖,藤黄酸对Jeko-1细胞增殖抑制率在低浓度组(0.065、0.125、0.25μg/ml)与对照组比较差异不显著(P>0.05),较高浓度组(0.5、1.0、2.0、4.0μg/ml)与对照组比较差异显著(P<0.05)：藤黄酸对正常人骨髓单个核细胞加药组与对照组比较,差异均无显著性(P>0.05)。藤黄酸可下调Jeko-1细胞Ki67的表达,且呈药物浓度依赖性。
2.藤黄酸作用于Jeko-1细胞株24h后呈典型凋亡形态学改变,各浓度(0、0.5、1.0、2.0、4.0μg/ml藤黄酸对Jeko-1细胞作用24h的细胞周期未见明显影响。
3.藤黄酸呈浓度依赖性增高Jeko-1细胞株的损伤线粒体跨膜电位(△ψm)水平。
4.藤黄酸作用JeKo-1细胞24小时,用药标本较对照标本的caspase-3、caspase-8和caspase-9活化比例明显升高(p<0.05)。caspase-3、caspase-8、和caspase-9的活化呈现浓度依赖性。
5.藤黄酸作用Jeko-1细胞24h后,随着藤黄酸浓度的增高,Bcl-2蛋白表达逐渐下降,而Bax蛋白表达逐渐增强。与对照组相比,在1μg/ml浓度时Bax/Bcl-2蛋白比值明显增高(P<0.05)。
[结论]
1.藤黄酸呈浓度依赖性抑制JeKo-1细胞的增殖。
2.藤黄酸呈浓度依耐性诱导JeKo-1细胞凋亡,机理是通过线粒体通路和膜受体通路诱导Jeko-1细胞凋亡,其诱导凋亡作用并非通过特异的细胞周期阻滞来实现。
3.藤黄酸诱导人套细胞淋巴瘤Jeko-1细胞凋亡时,主要通过活化Caspase-3、Caspase-8, Caspase-9和受损△ψm增加途径而实现诱导细胞凋亡,藤黄酸通过减低JeKo-1细胞中Bcl-2蛋白的水平,上调Bax蛋白的水平诱导细胞凋亡。
[Objective] To study the mechanisms in gambogic acid (GA)-induced JeKo-1human Mantle Cell Lymphoma cell apoptosis in vitro.
[Methods] the proliferation of GA-treated Jeko-1cells was measured by CCK-8assay and ki-67immunocytochemical detection. Appotosis, cell cycle and mitochondrial membrane potential were measured by flow cytometric analysis. Caspase-3,-8and-9were detected by colorimetric assay. Bcl-2and Bax were analyzed by Western blot.
[Results]
1. GA inhibited Jeko-1cells' growth in a time-and dose-dependent manner. Lower GA concentration (0.065、0.125、0.25μg/ml) could not inhibit the proliferation of Jeko-1cells(P>0.05). Higher GA(0.5、1.0、2.0、4.0μg/ml) concentrationcould inhibit the proliferation of Jeko-1cells (P<0.05).
2. GA did not significantly influence the cell cycle of Jeko-1cell lines at the concentration of0、0.5、1.0、2.0、4.0μg/ml for24h.
3. The typical apoptosis morphology change could be visualized after Jeko-1cell lines were incubated with GA. GA induces apoptosis in Jeko-1cells, which was involved in reducing the membrane potential of mitochondria,
4. GA increased the apoptosis rate of Jeko-1cell line and increased activated caspase-3, caspase-8, caspase-9positive cell number for different degree in24h.
5. There was a significant decrease in Bcl-2expression and increase in Bax expression in a dose-dependent manner after the GA treatment on Jeko-1cell for24h. Compared with the control group, with the concentration of1ug/ml, ratio between Bax and Bcl-2protein increased significantly (P<0.05).
[Conclusion]
1. GA has inhibitive effect on Jeko-1cell lines' growth in a concentration dependent manner in vitro.
2. GA induces apoptosis on Jeko-1cell lines in a concentration dependent manner. The Mechanism is through the mitochondrial pathway and membrane receptor pathway induce Jeko-1cell apoptosis.The cell cycles are not disturbed obviously in Jeko-1cell lines.
3. GA induced apoptosis in human MCL Jeko-1cells by regulating Bcl-2/Bax and activating caspase-3,-8and-9via mitochondrial pathway without affecting cell cycle.
引文
[1]沈志祥,朱雄增.恶性淋巴瘤[M].人民卫生出版社,2011：5.
[2]Swerdlow S H, Campo E, Harris N L, et al. Eds. World Health Organization classification of tumors of haematopoietic and lymphoid tissues[M]. Lyon:IARC,2008.
[3]邓成珊,周霭祥.当代中西医结合血液病学[M].北京：中国医药科技出版社,1996：7-11
[4]王祥麒,王俊涛,韩倩倩.恶性淋巴瘤的中医药治疗策略探讨[J].辽宁中医杂志,2011,38(9)1797-1798.
[5]朴炳奎.恶性淋巴瘤的中医诊治体会[J].江苏中医院杂志,2008,40(9)：5-6.
[6]陈信义,李冬云.恶性淋巴瘤的中西医结合治疗对策[M].北京：化学工业出版社,2008：7-11.
[7]张敏,孙尚见治疗恶性淋巴瘤经验[J].Clinical Journal of Chinese Medicine,2012,4(14):56-58.
[8]潘娟,甘欣锦.中医药在恶性淋巴瘤整合治疗中的作用[J].光明中医,2011,26(5)：876-877.
[9]薛爱珍,杨伟涛,罗秀素主任医师治疗恶性淋巴瘤经验[J].辽宁中医药大学学报,2010,12(6)174-175.
[10]章亚成,沈群,吴萸.恶性淋巴瘤中医证治思路探讨[J].浙江中医杂志,2010,45(4)256-257.
[11]陈敏.中医药治疗白血病的研究进展[J].实用中医内科杂志2011,25(5)32-35.
[12]Michel L, Dupuy A, Jean-Louis F, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells:evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C) [J]. J Invest Dermatol.2003; 121(4):881-893.
[13]杨宁蓉,秦叔逵,钱军.亚砷酸治疗B细胞非霍奇金淋巴瘤获缓解3例[J].白血病.淋巴瘤,2005；14：104-105
[14]林飞,李道睿,吴皓,等.基于信息挖掘技术对林洪生主任医师辨治恶性淋巴瘤临床用药规律初步总结[J].辽宁中医药大学学报,2012,14(9)64-67
[15]董茂芝,韩雪华.中西医结合治疗恶性淋巴瘤105例[J].辽宁中医杂志,2003,30(2)：135.
[16]杨企铮,贾淑杰,李德华.中药藤黄的近代研究[J].中国肿瘤临床,1994,21(6)：464-466.
[17]王鸣,冯煦,赵友谊.中药藤黄的研究和应用[J].中国野生植物资源,2003,22(1)：1-3.
[18]李念光,尤启冬,黄雪峰.藤黄酸构效关系的研究[J].中国天然药物杂志,2008,6(1)：37—42.
[19]张谨,王永泉.藤黄酸对肿瘤细胞诱导分化作用的探讨[J].实用癌症杂志,2003,18(1)：9-10.
[20]Qiang L, Yang Y, You QD, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid:a in vitro and vivo study [J]. Biochem Pharmacol,2008,75:1083-1092.
[21]Yi TF, Yi ZF, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling[J]. Cancer Res,2008,68(6):1843-1850.
[22]Yu J, Guo QL, You QD, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells [J]. Cancer Chemother Pharmacol,2006, 58(4):434-43.
[23]曲宝玺,纪运中,章萍,等.藤黄Ⅱ号对白血病L1210细胞杀伤动力学研究Ⅰ-显微分光光度计观察[J].中国肿瘤临床,1991(1)：53-56.
[24]Wang T, Wei J, Qian X, et al. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells [J]. Cancer Lett,2008,262(2):214-22.
[25]舒文秀,陈燕,何静,等.藤黄酸对急性白血病细胞U937增殖和凋亡的影响及对核孔蛋白Nup88的调控作用[J].中草药,2008,39(1)：74—78.
[26]舒文秀,陈燕,何静,等.藤黄酸调节急性白血病细胞HL-60核孔蛋白Nup88的意义[J].中华肿瘤杂志,2008,30(7)：484-48.
[27]张启国,李翠萍,陈军浩,等.藤黄酸对K562细胞的凋亡诱导及其作用研究[J].中国实验血液学杂志2009,12(6)：1443-1447.
[28]崔国惠,舒文秀,吴青,等.藤黄酸对K562细胞hERG钾通道蛋白的调控作用[J].中草药,2009,40(6)：915-919.
[29]Li R, Chen Y, Zeng LL, et al. Gambogic acid induces GO/GI arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[30]Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway[J]. Blood,2007, 110(10):3517-25.
[31]Zhai DY, Jin CF, Shiau CW, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins[J].Mol Cancer Ther,2008,7(6):1639-46.
[32]TAO Z, ZHOU Y, LU J, et al. caspase-8 Preferentially Senses the Apoptosis-Inducing Action of NG-18, A Gambogic Acid Derivative, in Human Leukemia HL-60 Cells[J]. Cancer Biol Ther,2007,6:691-696.
[33]HAN Q B, YANG L, WANG Y L, et al. A Pair of Novel Cytotoxic Polyprenylated Xantho ne Epimers fr om Gambo ges [J]. Chemistry & Bidiversity,2006,3:101-105.
[34]BAT OVA A, LAM T, WASCH OLOWSKI V, et al. Synthesis and evaluation of caged Garcinia xanthones [J]. Org Biomol Chem,2007,5:494-500.
[35]张启国,李翠平,陈军浩,等.藤黄酸诱导Raji细胞凋亡的机制[J].白血病.淋巴瘤,2009,11(18)：643-653.
[36]王勇,陈燕,吴小建,等.藤黄酸抑制NF-κB信号通路阻滞Raji细胞周期进程[J].华中科技大学学报,2009,38(2)：169-172
[37]杨永公,张启国,欧阳建,等.藤黄酸诱导骨髓瘤U 266细胞凋亡及机制研究[J].中华临床医师杂志,2011,5：996-1001.
[38]洪铁艳,陈宝安,高冲.藤黄酸对MUTZ-1细胞生长抑制作用及其机理研究[J].中国实验血液学杂志,2009,17(2)：373-376.
[1]南京医学院.药材学[M].北京：人民卫生出版社,1960：1161.
[2]李时珍.本草纲目[M].2册.北京：人民卫生出版社,1977：1344.
[3]赵学敏.本草纲目拾遗[M].北京：人民卫生出版社,1957：204.
[4]王鸣,冯煦,赵友谊,等.中药藤黄的研究与利用[J].中国野生植物资源,2003(22)：1-4.
[5]郭青龙,吴照球,俞刚.藤黄酸对实验性动物造血功能及免疫功能的影响[J].中国天然药物,2003,1(4)：37-40.
[6]项守仁,程廷楷,黄永昌,等.藤黄酸对肉瘤180及艾氏腹水癌的作用(“736-2”研究之一)[J].江西医学院学报,1980,5(1)：17-21.
[7]Zhao Q, Yang Y, Yu J, et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells [J]. Cancer Lett,2008,262(2):223-31.
[8]Xu X, Liu Y, Wang L, et al. Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells [J]. Int J Dermatol, 2009,48(2):186-192.17.
[9]陈婷梅,祝彼得.抗白血病中药及天然药物的研究现状[J].中国中西医结合杂志,1995,15(5)：317-320.18.
[10]翟万银,周双雯,贾春平,等.藤黄酸抗肿瘤细胞生物学机制[J].细胞生物学杂志,2009,31(4)：481-485.
[11]舒文秀,陈燕,何静,等.藤黄酸对急性白血病细胞U937增殖和凋亡的影响及对核孔蛋白Nup88的调控作用[J].中草药,2008,39(1)：74-78.
[12]舒文秀,陈燕,何静,等.藤黄酸调节急性白血病细胞HL-60核孔蛋白Nup88的意义[J].中华肿瘤杂志,2008,30(7)：484-48
[13]崔国惠,舒文秀,吴青,等.藤黄酸对K562细胞hERG钾通道蛋白的调控作用[J].中草药,2009,40(6)：915-919
[14]Li R,Chen Y,Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[15]Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway [J]. Blood, 2007,110 (10):3517-25.
[16]Zhai DY, Jin CF, Shiau CW, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins [J]. Mol Cancer Ther,2008,7(6):1639-46.
[17]TAO Z, ZHOU Y, LU J, et al. caspase-8 Preferentially Senses the Apoptosis-Inducing Action of NG-18, A Gambogic Acid Derivative, in Human Leukemia HL-60 Cells[J]. Cancer Biol Ther,2007,6:691-696.
[18]HAN Q B, YANG L, WANG Y L, et al. A Pair of Novel Cytotoxic Polyprenylated Xantho ne Epimers fr om Gambo ges [J]. Chemistry & Bidiversity,2006,3:101-105.
[19]张启国.藤萸酸抗恶性血液病作用及机理研究[D].南京中医药大学博士学位论文.2010年12月.
[20]Gerdes J,Lemke H,Baisch H,et al.Ceil cycle analysis of a cell proliferation associated human unclear antigen defined by the mo-noelonalahtibody Ki-67[J].J Immunol,1984,133(13):1710-1715.
[1]Jaeffee ES, Harris NL, Stein H, et al. World health organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues [M]. Lyon:I ARC Press,2001:215-289.
[2]王海,张曙,石群立.套细胞淋巴瘤研究进展[J].中国肿瘤,2008,17(12)：L1032-1035
[3]郑振,熊小亮.套细胞淋巴瘤研究进展[J].实用临床医学,2007,(8)4：130-134
[4]周立强,李陶.恶性淋巴瘤[M].中国医药科技出版社,2010：135.
[5]沈志祥,朱雄增.恶性淋巴瘤[M].人民卫生出版社,2011：597.
[6]Kerr JF, Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics [J].Br J Cancer,1972,26 (4):57-239.
[7]陈哗光,张传茂,陈伶.分子细胞生物学[M].清华大学出版社,535-537.
[8]Hickman JA.Apoptosis induced by anticancer drugs [J].Cancer Metastasis Rev,1992,11(2):121-39.
[9]Wu ZQ,Guo QL,You QD,et al.Gambogic acid inhibits pmlifbmRion of human lung carcinoma SPC—AI cells in vivo and in vitro and represses telomerase activity and teiomerase reverse transcriptase mRNA expression in the cells[J].Biol Pharm Bull,2004,27(11):1769-1774.
[10]Zhai D, Jin C, Shiau CW,et al.Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins[J]. Mol Cancer Ther,008,7(6):1639-1646.
[11]Wang Y,Chen Y,Chen Z,et al.Gambogic acid induces death inducer-obliterator 1-mediated apoptosis in Jurkat T cells[J].Acts Pharmacol Sin.2008,29(3):349-354.
[12]Xu X,Liu Y,Wang L,et al.Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells[J].Int J Dermatol,2009,48(2):186-192.
[13]Kasibhatla S.Jesson KA.Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid[J].Proc Nail AcadSci USA,2005,102(34):12095-12100.
[14]Pandey MK,Sung B,Ahn KS.et al.Gambogic acid,a novel ligand for transferrin receptor.potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway [J].Blood,2007,110(10):3517-3525.
[15]ShuW,Chen Y, Li R,et al.Involvement of regulations of nulcophosmin and nucleoporins in gamboglc acid-induced apeptosis in Jurkat cells[J]. Basic ClinPharmacol Toxicol,2008,103(6):530-537.
[16]Gu H,You Q.Liu w,et al.Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in 1-122 transplanted mice[J].Intlmmunopharmacol,2008,8(11):1493-1502.
[17]廖章萍.白黎芦醇抗心肌缺血再灌注损伤的线粒体机制研究[D].南昌大学博士研究生学位论文,2011年6月
[18]Li R, Chen Y, Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[19]Zhang H Z, Kasibhatla S, Wang Y, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay[J].Bioorg Med Chem,2004,12:309-317.
[20]Lin Qiwei.Themitoehondrion and apoptosis [J].Bocihemistry and biophysics newspaper,1999, 31(2):116-118.
[21]Ricci JE.Mitoehondrial functions during cell death,a complex(Ⅰ-Ⅴ)dilemrna[J].Cell Death Differ,2003, 10:488-492.
[22]陈津,张如松.细胞凋亡机制概述[J].中华中医药学刊,2011,29(4)：886-889.
[23]Bensassi F,Gallerne C,Dein OS, et al. Mechanism of Alternariolmonomethyl ether-induced mitochondrial apoptosis in human colon carcinoma cells [J]. Toxicology. Dec,2011,290(2-3):231-241.
[24]陈慧莉,李建华,王树庆.线粒体跨膜电位和细胞凋亡相关性的研究.医学综述[J].2007,13(14)：1041-1043.
[25]石静,卿晨.线粒体膜电位改变与细胞凋亡[J].中国民族民间医药,2011,4(7)：20-21.
[26]赵丹,贺莉芳,刘晖.线粒体、细胞色素C、Caspase与细胞凋亡[J].医学动物防制,2012,28(12)1337-1340.
[27]赵瑞杰,李引乾,王会.Caspase家族与细胞凋亡的关系[J].中国畜牧杂志,2010,46(17).
[28]Scatena R, Bottoni P, Botta G, e t al. The role of mitochondria in pharmacotoxicology:a reevaluation of an old, newly emerging topic [J].Am J Physiol Cell Physiol,2007, (293):C 12-21.
[29]Hacker G, Paschen SA. Therapeutic targets in the mitochondrial apoptotic pathway [J].Expert OpinTher Targets,2007, (11):515-526.
[30]Cryns V, Yuan J. Protease to die for [J].Genes Dev,1998,12(11):1551-1570.
[31]郭海,才秀莲.Caspase家族与细胞凋亡及诱发因素研究进展[J].河南职工医学院学报,2012,24(6)847-850.
[32]Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies [J]. Blood,2005,106 (2):408-418.
[33]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death [J]. Cell,1993,74:609-619.
[34]Adams JM, Cory S.The Bcl-2 apoptotic switch in cancer development and therapy [J]. Oncogene,2007, 26:1324-1337.
[35]Zhan Q, Bieszczad CK, Bae I, et al. Induction of BCL2 family member MCL1 as an early response to DNA damage [J]. Oncogene,1997,14:1031-1039
[36]Adams JM, Cory S.The Bcl-2 protein family:Arbitersof cell survival [J]. Science,1998,281:1322-1326.
[37]Green D, Kroemer G. The central executioners of apoptosis:caspases or mitochondria? [J].Trends Cell Biol.1998,8:267-271.
[38]Hangen E, Blomgren K, Benit P, et al. Life with or without AIF[J]. Trends in Bocihemical Sciences, 2010(5):278-287.
[39]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death[J].Cell,1993,74(4):609-619
[40]Mizushima N, Yamamoto A, Hatano M,etal.Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells[J].J Cell Biol,2001,152:657-667.
[41]Korsmeyer SJ, Shutter JR, Veis DJ,et al.Bcl-2/Bax:a rheostat that regulates all anti-oxidant pathway and cell death[J].Semin Cancer Biol,1993,4(6):327-332.
[42]胡硕,胡成平.线粒体与细胞凋产的研究进展[J].国际呼吸杂志,2006,26(6)：463-466.
[43]Crawford LV, Pirn DC, Gurney EG, et al. Detection of a common feature in several human tumor cell lines-a 53,000-Dalton protein [J]. Proc Natl Acad Sci USA,1981,78(1):41-45.
[44]Finlay CA, Hinds PW, Levine AJ.The p53 proto-oncogene can act as a suppressor of transformation [J]. Cel,1989,57(7):1083-1093.
[45]Nigro JM, Baker S J, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types [J].Nature,1989,342(6250):705-708.
[46]Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer:a review [J]. Int J Cancer,1994,57:1-9.
[47]周向东,沈寒放,谭骏.p53丛因缺失和248位密码子点突变与肺癌发生和预后间关系的研究[J].中国肿瘤临床,1997,24(6)：415-418.
[48]Wang JY, Lin SR, Hsich JS, et al. Mutations of p53 gene in gastric carcinoma in Taiwan [J]. Anticancer Res,2003,21(1B):513-520.
[49]Chen PL,Chen YM,Bookstein R,et al.Genetic mechanisms of tumor Suppression by the human P53 gene[J].Science,1990,250(4987):1576.
[50]Soussi T, Loano G.P53 mutation heterogenety in cancer [J]. Biochem Biophysier Commun,2005, 331(3):534.
[51]Mutlashewski G,Banks L, Pim D, et al.Analysis of human P53 Prot ein and mRNA leves in normal and transformed cells[J].Eur.J Bioehem,1986,154:665
[52]Malcikova J, Smardova J, Pekova S, et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia[J]. Mol Immunol,2008; 45(5):1525-1529
[53]Hesham M, Timothy J, L. Jeffrey, et al. Characterization of 4 Mantle Cell Lymphoma Cell Lines Establishment of an In Vitro Study Model [J]. Arch Pathol Lab Med,2003,127(4):424-431
[54]Daniela C,Alderto Z, Alice P, et al.Induction of Apoptosis in Jeko-1 Mantle Cell Lymphoma Cell Line by Resveratrol:A Proteomic Analysis [J].Journal of Proteome Research,2008,7(7):2670-2680
[55]周兰贞,陈红波,李庆林.藤黄酸的抗肿瘤作用机制研究进展[J].安徽医药,2011,15(3)：269-271.
[2]Swerdlow S H, Campo E, Harris N L, et al. Eds. World Health Organization classification of tumors of haematopoietic and lymphoid tissues[M]. Lyon:IARC,2008.
[3]邓成珊,周霭祥.当代中西医结合血液病学[M].北京：中国医药科技出版社,1996：7-11
[4]王祥麒,王俊涛,韩倩倩.恶性淋巴瘤的中医药治疗策略探讨[J].辽宁中医杂志,2011,38(9)1797-1798.
[5]朴炳奎.恶性淋巴瘤的中医诊治体会[J].江苏中医院杂志,2008,40(9)：5-6.
[6]陈信义,李冬云.恶性淋巴瘤的中西医结合治疗对策[M].北京：化学工业出版社,2008：7-11.
[7]张敏,孙尚见治疗恶性淋巴瘤经验[J].Clinical Journal of Chinese Medicine,2012,4(14):56-58.
[8]潘娟,甘欣锦.中医药在恶性淋巴瘤整合治疗中的作用[J].光明中医,2011,26(5)：876-877.
[9]薛爱珍,杨伟涛,罗秀素主任医师治疗恶性淋巴瘤经验[J].辽宁中医药大学学报,2010,12(6)174-175.
[10]章亚成,沈群,吴萸.恶性淋巴瘤中医证治思路探讨[J].浙江中医杂志,2010,45(4)256-257.
[11]陈敏.中医药治疗白血病的研究进展[J].实用中医内科杂志2011,25(5)32-35.
[12]Michel L, Dupuy A, Jean-Louis F, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells:evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C) [J]. J Invest Dermatol.2003; 121(4):881-893.
[13]杨宁蓉,秦叔逵,钱军.亚砷酸治疗B细胞非霍奇金淋巴瘤获缓解3例[J].白血病.淋巴瘤,2005；14：104-105
[14]林飞,李道睿,吴皓,等.基于信息挖掘技术对林洪生主任医师辨治恶性淋巴瘤临床用药规律初步总结[J].辽宁中医药大学学报,2012,14(9)64-67
[15]董茂芝,韩雪华.中西医结合治疗恶性淋巴瘤105例[J].辽宁中医杂志,2003,30(2)：135.
[16]杨企铮,贾淑杰,李德华.中药藤黄的近代研究[J].中国肿瘤临床,1994,21(6)：464-466.
[17]王鸣,冯煦,赵友谊.中药藤黄的研究和应用[J].中国野生植物资源,2003,22(1)：1-3.
[18]李念光,尤启冬,黄雪峰.藤黄酸构效关系的研究[J].中国天然药物杂志,2008,6(1)：37—42.
[19]张谨,王永泉.藤黄酸对肿瘤细胞诱导分化作用的探讨[J].实用癌症杂志,2003,18(1)：9-10.
[20]Qiang L, Yang Y, You QD, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid:a in vitro and vivo study [J]. Biochem Pharmacol,2008,75:1083-1092.
[21]Yi TF, Yi ZF, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling[J]. Cancer Res,2008,68(6):1843-1850.
[22]Yu J, Guo QL, You QD, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells [J]. Cancer Chemother Pharmacol,2006, 58(4):434-43.
[23]曲宝玺,纪运中,章萍,等.藤黄Ⅱ号对白血病L1210细胞杀伤动力学研究Ⅰ-显微分光光度计观察[J].中国肿瘤临床,1991(1)：53-56.
[24]Wang T, Wei J, Qian X, et al. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells [J]. Cancer Lett,2008,262(2):214-22.
[25]舒文秀,陈燕,何静,等.藤黄酸对急性白血病细胞U937增殖和凋亡的影响及对核孔蛋白Nup88的调控作用[J].中草药,2008,39(1)：74—78.
[26]舒文秀,陈燕,何静,等.藤黄酸调节急性白血病细胞HL-60核孔蛋白Nup88的意义[J].中华肿瘤杂志,2008,30(7)：484-48.
[27]张启国,李翠萍,陈军浩,等.藤黄酸对K562细胞的凋亡诱导及其作用研究[J].中国实验血液学杂志2009,12(6)：1443-1447.
[28]崔国惠,舒文秀,吴青,等.藤黄酸对K562细胞hERG钾通道蛋白的调控作用[J].中草药,2009,40(6)：915-919.
[29]Li R, Chen Y, Zeng LL, et al. Gambogic acid induces GO/GI arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[30]Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway[J]. Blood,2007, 110(10):3517-25.
[31]Zhai DY, Jin CF, Shiau CW, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins[J].Mol Cancer Ther,2008,7(6):1639-46.
[32]TAO Z, ZHOU Y, LU J, et al. caspase-8 Preferentially Senses the Apoptosis-Inducing Action of NG-18, A Gambogic Acid Derivative, in Human Leukemia HL-60 Cells[J]. Cancer Biol Ther,2007,6:691-696.
[33]HAN Q B, YANG L, WANG Y L, et al. A Pair of Novel Cytotoxic Polyprenylated Xantho ne Epimers fr om Gambo ges [J]. Chemistry & Bidiversity,2006,3:101-105.
[34]BAT OVA A, LAM T, WASCH OLOWSKI V, et al. Synthesis and evaluation of caged Garcinia xanthones [J]. Org Biomol Chem,2007,5:494-500.
[35]张启国,李翠平,陈军浩,等.藤黄酸诱导Raji细胞凋亡的机制[J].白血病.淋巴瘤,2009,11(18)：643-653.
[36]王勇,陈燕,吴小建,等.藤黄酸抑制NF-κB信号通路阻滞Raji细胞周期进程[J].华中科技大学学报,2009,38(2)：169-172
[37]杨永公,张启国,欧阳建,等.藤黄酸诱导骨髓瘤U 266细胞凋亡及机制研究[J].中华临床医师杂志,2011,5：996-1001.
[38]洪铁艳,陈宝安,高冲.藤黄酸对MUTZ-1细胞生长抑制作用及其机理研究[J].中国实验血液学杂志,2009,17(2)：373-376.
[1]南京医学院.药材学[M].北京：人民卫生出版社,1960：1161.
[2]李时珍.本草纲目[M].2册.北京：人民卫生出版社,1977：1344.
[3]赵学敏.本草纲目拾遗[M].北京：人民卫生出版社,1957：204.
[4]王鸣,冯煦,赵友谊,等.中药藤黄的研究与利用[J].中国野生植物资源,2003(22)：1-4.
[5]郭青龙,吴照球,俞刚.藤黄酸对实验性动物造血功能及免疫功能的影响[J].中国天然药物,2003,1(4)：37-40.
[6]项守仁,程廷楷,黄永昌,等.藤黄酸对肉瘤180及艾氏腹水癌的作用(“736-2”研究之一)[J].江西医学院学报,1980,5(1)：17-21.
[7]Zhao Q, Yang Y, Yu J, et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells [J]. Cancer Lett,2008,262(2):223-31.
[8]Xu X, Liu Y, Wang L, et al. Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells [J]. Int J Dermatol, 2009,48(2):186-192.17.
[9]陈婷梅,祝彼得.抗白血病中药及天然药物的研究现状[J].中国中西医结合杂志,1995,15(5)：317-320.18.
[10]翟万银,周双雯,贾春平,等.藤黄酸抗肿瘤细胞生物学机制[J].细胞生物学杂志,2009,31(4)：481-485.
[11]舒文秀,陈燕,何静,等.藤黄酸对急性白血病细胞U937增殖和凋亡的影响及对核孔蛋白Nup88的调控作用[J].中草药,2008,39(1)：74-78.
[12]舒文秀,陈燕,何静,等.藤黄酸调节急性白血病细胞HL-60核孔蛋白Nup88的意义[J].中华肿瘤杂志,2008,30(7)：484-48
[13]崔国惠,舒文秀,吴青,等.藤黄酸对K562细胞hERG钾通道蛋白的调控作用[J].中草药,2009,40(6)：915-919
[14]Li R,Chen Y,Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[15]Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway [J]. Blood, 2007,110 (10):3517-25.
[16]Zhai DY, Jin CF, Shiau CW, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins [J]. Mol Cancer Ther,2008,7(6):1639-46.
[17]TAO Z, ZHOU Y, LU J, et al. caspase-8 Preferentially Senses the Apoptosis-Inducing Action of NG-18, A Gambogic Acid Derivative, in Human Leukemia HL-60 Cells[J]. Cancer Biol Ther,2007,6:691-696.
[18]HAN Q B, YANG L, WANG Y L, et al. A Pair of Novel Cytotoxic Polyprenylated Xantho ne Epimers fr om Gambo ges [J]. Chemistry & Bidiversity,2006,3:101-105.
[19]张启国.藤萸酸抗恶性血液病作用及机理研究[D].南京中医药大学博士学位论文.2010年12月.
[20]Gerdes J,Lemke H,Baisch H,et al.Ceil cycle analysis of a cell proliferation associated human unclear antigen defined by the mo-noelonalahtibody Ki-67[J].J Immunol,1984,133(13):1710-1715.
[1]Jaeffee ES, Harris NL, Stein H, et al. World health organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues [M]. Lyon:I ARC Press,2001:215-289.
[2]王海,张曙,石群立.套细胞淋巴瘤研究进展[J].中国肿瘤,2008,17(12)：L1032-1035
[3]郑振,熊小亮.套细胞淋巴瘤研究进展[J].实用临床医学,2007,(8)4：130-134
[4]周立强,李陶.恶性淋巴瘤[M].中国医药科技出版社,2010：135.
[5]沈志祥,朱雄增.恶性淋巴瘤[M].人民卫生出版社,2011：597.
[6]Kerr JF, Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics [J].Br J Cancer,1972,26 (4):57-239.
[7]陈哗光,张传茂,陈伶.分子细胞生物学[M].清华大学出版社,535-537.
[8]Hickman JA.Apoptosis induced by anticancer drugs [J].Cancer Metastasis Rev,1992,11(2):121-39.
[9]Wu ZQ,Guo QL,You QD,et al.Gambogic acid inhibits pmlifbmRion of human lung carcinoma SPC—AI cells in vivo and in vitro and represses telomerase activity and teiomerase reverse transcriptase mRNA expression in the cells[J].Biol Pharm Bull,2004,27(11):1769-1774.
[10]Zhai D, Jin C, Shiau CW,et al.Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins[J]. Mol Cancer Ther,008,7(6):1639-1646.
[11]Wang Y,Chen Y,Chen Z,et al.Gambogic acid induces death inducer-obliterator 1-mediated apoptosis in Jurkat T cells[J].Acts Pharmacol Sin.2008,29(3):349-354.
[12]Xu X,Liu Y,Wang L,et al.Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells[J].Int J Dermatol,2009,48(2):186-192.
[13]Kasibhatla S.Jesson KA.Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid[J].Proc Nail AcadSci USA,2005,102(34):12095-12100.
[14]Pandey MK,Sung B,Ahn KS.et al.Gambogic acid,a novel ligand for transferrin receptor.potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway [J].Blood,2007,110(10):3517-3525.
[15]ShuW,Chen Y, Li R,et al.Involvement of regulations of nulcophosmin and nucleoporins in gamboglc acid-induced apeptosis in Jurkat cells[J]. Basic ClinPharmacol Toxicol,2008,103(6):530-537.
[16]Gu H,You Q.Liu w,et al.Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in 1-122 transplanted mice[J].Intlmmunopharmacol,2008,8(11):1493-1502.
[17]廖章萍.白黎芦醇抗心肌缺血再灌注损伤的线粒体机制研究[D].南昌大学博士研究生学位论文,2011年6月
[18]Li R, Chen Y, Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt path-way in K562 leukemia cells[J]. Toxicology,2009,262(2):98-105
[19]Zhang H Z, Kasibhatla S, Wang Y, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay[J].Bioorg Med Chem,2004,12:309-317.
[20]Lin Qiwei.Themitoehondrion and apoptosis [J].Bocihemistry and biophysics newspaper,1999, 31(2):116-118.
[21]Ricci JE.Mitoehondrial functions during cell death,a complex(Ⅰ-Ⅴ)dilemrna[J].Cell Death Differ,2003, 10:488-492.
[22]陈津,张如松.细胞凋亡机制概述[J].中华中医药学刊,2011,29(4)：886-889.
[23]Bensassi F,Gallerne C,Dein OS, et al. Mechanism of Alternariolmonomethyl ether-induced mitochondrial apoptosis in human colon carcinoma cells [J]. Toxicology. Dec,2011,290(2-3):231-241.
[24]陈慧莉,李建华,王树庆.线粒体跨膜电位和细胞凋亡相关性的研究.医学综述[J].2007,13(14)：1041-1043.
[25]石静,卿晨.线粒体膜电位改变与细胞凋亡[J].中国民族民间医药,2011,4(7)：20-21.
[26]赵丹,贺莉芳,刘晖.线粒体、细胞色素C、Caspase与细胞凋亡[J].医学动物防制,2012,28(12)1337-1340.
[27]赵瑞杰,李引乾,王会.Caspase家族与细胞凋亡的关系[J].中国畜牧杂志,2010,46(17).
[28]Scatena R, Bottoni P, Botta G, e t al. The role of mitochondria in pharmacotoxicology:a reevaluation of an old, newly emerging topic [J].Am J Physiol Cell Physiol,2007, (293):C 12-21.
[29]Hacker G, Paschen SA. Therapeutic targets in the mitochondrial apoptotic pathway [J].Expert OpinTher Targets,2007, (11):515-526.
[30]Cryns V, Yuan J. Protease to die for [J].Genes Dev,1998,12(11):1551-1570.
[31]郭海,才秀莲.Caspase家族与细胞凋亡及诱发因素研究进展[J].河南职工医学院学报,2012,24(6)847-850.
[32]Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies [J]. Blood,2005,106 (2):408-418.
[33]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death [J]. Cell,1993,74:609-619.
[34]Adams JM, Cory S.The Bcl-2 apoptotic switch in cancer development and therapy [J]. Oncogene,2007, 26:1324-1337.
[35]Zhan Q, Bieszczad CK, Bae I, et al. Induction of BCL2 family member MCL1 as an early response to DNA damage [J]. Oncogene,1997,14:1031-1039
[36]Adams JM, Cory S.The Bcl-2 protein family:Arbitersof cell survival [J]. Science,1998,281:1322-1326.
[37]Green D, Kroemer G. The central executioners of apoptosis:caspases or mitochondria? [J].Trends Cell Biol.1998,8:267-271.
[38]Hangen E, Blomgren K, Benit P, et al. Life with or without AIF[J]. Trends in Bocihemical Sciences, 2010(5):278-287.
[39]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death[J].Cell,1993,74(4):609-619
[40]Mizushima N, Yamamoto A, Hatano M,etal.Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells[J].J Cell Biol,2001,152:657-667.
[41]Korsmeyer SJ, Shutter JR, Veis DJ,et al.Bcl-2/Bax:a rheostat that regulates all anti-oxidant pathway and cell death[J].Semin Cancer Biol,1993,4(6):327-332.
[42]胡硕,胡成平.线粒体与细胞凋产的研究进展[J].国际呼吸杂志,2006,26(6)：463-466.
[43]Crawford LV, Pirn DC, Gurney EG, et al. Detection of a common feature in several human tumor cell lines-a 53,000-Dalton protein [J]. Proc Natl Acad Sci USA,1981,78(1):41-45.
[44]Finlay CA, Hinds PW, Levine AJ.The p53 proto-oncogene can act as a suppressor of transformation [J]. Cel,1989,57(7):1083-1093.
[45]Nigro JM, Baker S J, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types [J].Nature,1989,342(6250):705-708.
[46]Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer:a review [J]. Int J Cancer,1994,57:1-9.
[47]周向东,沈寒放,谭骏.p53丛因缺失和248位密码子点突变与肺癌发生和预后间关系的研究[J].中国肿瘤临床,1997,24(6)：415-418.
[48]Wang JY, Lin SR, Hsich JS, et al. Mutations of p53 gene in gastric carcinoma in Taiwan [J]. Anticancer Res,2003,21(1B):513-520.
[49]Chen PL,Chen YM,Bookstein R,et al.Genetic mechanisms of tumor Suppression by the human P53 gene[J].Science,1990,250(4987):1576.
[50]Soussi T, Loano G.P53 mutation heterogenety in cancer [J]. Biochem Biophysier Commun,2005, 331(3):534.
[51]Mutlashewski G,Banks L, Pim D, et al.Analysis of human P53 Prot ein and mRNA leves in normal and transformed cells[J].Eur.J Bioehem,1986,154:665
[52]Malcikova J, Smardova J, Pekova S, et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia[J]. Mol Immunol,2008; 45(5):1525-1529
[53]Hesham M, Timothy J, L. Jeffrey, et al. Characterization of 4 Mantle Cell Lymphoma Cell Lines Establishment of an In Vitro Study Model [J]. Arch Pathol Lab Med,2003,127(4):424-431
[54]Daniela C,Alderto Z, Alice P, et al.Induction of Apoptosis in Jeko-1 Mantle Cell Lymphoma Cell Line by Resveratrol:A Proteomic Analysis [J].Journal of Proteome Research,2008,7(7):2670-2680
[55]周兰贞,陈红波,李庆林.藤黄酸的抗肿瘤作用机制研究进展[J].安徽医药,2011,15(3)：269-271.